Wilsey Asset Management Inc. Has $23.88 Million Stake in Pfizer Inc. $PFE

Key Points

• Wilsey Asset Management Inc. has increased its stake in Pfizer Inc. by 4.6%, now holding 985,295 shares valued at approximately $23.88 million.
• Brighton Jones LLC has significantly boosted its position in Pfizer by 1,282.4%, acquiring over 618,000 shares during the fourth quarter, contributing to an overall institutional ownership of 68.36% in the company.
• Pfizer reported a quarterly earnings per share of $0.78, exceeding analysts' estimates, with a revenue of $14.65 billion, marking a 10.3% increase year-over-year.

Wilsey Asset Management Inc. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 4.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 985,295 shares of the biopharmaceutical company's stock after buying an additional 43,566 shares during the quarter. Pfizer accounts for about 4.4% of Wilsey Asset Management Inc.'s portfolio, making the stock its 14th largest holding. Wilsey Asset Management Inc.'s holdings in Pfizer were worth $23,884,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the period. Vident Advisory LLC bought a new position in Pfizer during the fourth quarter valued at about $248,000. Armis Advisers LLC bought a new position in Pfizer during the fourth quarter worth about $215,000. Finally, Heck Capital Advisors LLC bought a new position in Pfizer during the fourth quarter worth about $49,000. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE opened at $24.12 on Wednesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The business's fifty day simple moving average is $24.60 and its 200-day simple moving average is $24.18. The company has a market capitalization of $137.14 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.